SCHEDULE 13G: Leonite Fund I and Avi Geller Disclose 5.19% Passive Stake in Helius Medical Technologies
Beneficial Ownership Disclosure
Leonite Fund I, LP and Avi Geller have jointly filed a Schedule 13G, disclosing a beneficial ownership of 5.19% of Helius Medical Technologies, Inc.'s common shares.
Summary
- Leonite Fund I, LP, a Delaware limited partnership, and Avi Geller, an individual, have jointly filed a Schedule 13G.
- The filing discloses beneficial ownership of 163,055 shares of common stock in Helius Medical Technologies, Inc.
- This stake represents approximately 5.19% of the Issuer's outstanding common shares, based on 3,140,166 shares outstanding (excluding shares underlying warrants).
- Avi Geller, as the chief investment officer of Leonite Fund I, LP, holds sole voting and dispositive power over these shares.
- The acquisition of these securities is certified as not being for the purpose of changing or influencing the control of the issuer, indicating a passive investment.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a standard regulatory disclosure of a passive ownership stake, providing factual information without expressing positive or negative views on the company's performance or outlook.
Future Outlook
The document does not provide any forward-looking statements or guidance from Helius Medical Technologies, Inc. or the reporting persons regarding the company's future performance or strategic direction.
Industry Context
This filing is a standard disclosure of a significant passive ownership stake in a medical technology company. It does not provide specific insights into broader industry trends or competitive landscape, but indicates investor interest in Helius Medical Technologies, Inc.
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder may be viewed positively as it indicates investor confidence or interest in the company's stock. It also provides transparency regarding the ownership structure.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date of event which requires filing of this statement (acquisition of beneficial ownership exceeding 5%). |
| 06/09/2025 | Date the Schedule 13G statement was signed and filed. |
Keywords
Helius Medical Technologies, Leonite Fund I, Avi Geller, Schedule 13G, Beneficial Ownership, Common Shares, Passive Investment, SEC Filing, Medical Technology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.